According to an official notification issued by the Ministry of Personnel, Public Grievances and Pensions, Department of Personnel and Training, Dr Raghuvanshi will continue in his role on a contractual basis for one year from 1 March 2026.
“The Appointments Committee of the Cabinet has approved the proposal of the Department of Health and Family Welfare for the re-employment of Dr. Rajeev Singh Raghuvanshi as Drugs Controller (India), Central Drugs Standard Control Organization (CDSCO) on a contract basis for a further period of one year w.e.f. 01.03.2026, or till the appointment of a regular incumbent to the post, or until further orders, whichever is the earliest, by keeping the Recruitment Rules (RRs) for the post in abeyance,” it said.
The DCGI heads the Central Drugs Standard Control Organisation (CDSCO)which is responsible for ensuring quality drugs supply across the country. It also has authority to give approval to new drugs and regulating clinical trials.
Dr Raghuvanshi had joined the IPC as secretary-cum-scientific director on February 16, 2021.
He completed his Bachelors and Masters from IIT-BHU (formerly IT-BHU), Varanasi and PhD from the National Institute of Immunology, New Delhi.
After working for seven years at the National Institute of Immunology, he joined leading Indian multinational pharmaceutical company Ranbaxy Laboratories Ltd.After 12 years at Ranbaxy Laboratories, he moved to Dr Reddy’s Laboratories Ltd, Hyderabad, where he worked for 11 years.
Dr Raghuvanshi’s expertise lies in dosage form design and development, mainly in the domain of pharmaceutical innovation. He has been involved in development of different kind of products such as oral solids, oral liquids, topicals, injections, nasal sprays, auto-injectors, sublingual, mouth dissolve, extended release and delayed release for global markets.
More than 200 products developed by him and his teams are currently being sold in India, US, Europe and emerging markets.
